Tugce Balci Okcanoglu
Overview
Explore the profile of Tugce Balci Okcanoglu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
57
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kamer S, Yilmaz Susluer S, Balci Okcanoglu T, Kayabasi C, Ozmen Yelken B, Hoca S, et al.
Cancer Med
. 2023 Sep;
12(19):19874-19888.
PMID: 37754559
Background: The optimal radiobiological model, which assesses the biological effects of novel radiotherapy techniques that concurrently modify multiple physical factors, has not yet been defined. This study aimed to investigate...
2.
Kayabasi C, Yilmaz Susluer S, Balci Okcanoglu T, Ozmen Yelken B, Mutlu Z, Bagca B, et al.
Nutr Cancer
. 2022 May;
74(10):3679-3691.
PMID: 35608652
is used in folk medicine due to its anti-inflammatory, antimicrobial, and antioxidant properties. Ponatinib, an effective tyrosine kinase inhibitor in the treatment of chronic myeloid leukemia (CML), has severe side...
3.
Kayabasi C, Caner A, Yilmaz Susluer S, Balci Okcanoglu T, Ozmen Yelken B, Asik A, et al.
Med Oncol
. 2022 Jan;
39(3):29.
PMID: 35059859
LncRNAs are associated with malignancies with their tumor suppressor/oncogenic properties. Although many studies are conducted related to the mechanism of action for dasatinib and ponatinib in chronic myeloid leukemia (CML),...
4.
Kayabasi C, Ozmen Yelken B, Asik A, Balci Okcanoglu T, Sogutlu F, Gasimli R, et al.
Eur J Pharmacol
. 2021 Aug;
910:174446.
PMID: 34461124
Ponatinib is used for advanced treatment of chronic myeloid leukemia (CML), although low doses to prevent side effects do not suppress survival pathways and eradicate leukemia stem cells (LSCs). We...
5.
Balci Okcanoglu T, Kayabasi C, Gunduz C
Bosn J Basic Med Sci
. 2019 Jul;
20(1):56-62.
PMID: 31319040
Long non-coding RNAs (lncRNAs) are involved in a range of biological processes, such as cellular differentiation, migration, apoptosis, invasion, proliferation, and transcriptional regulation. The aberrant expression of lncRNAs plays a...
6.
Balci Okcanoglu T, Gunduz C
Biomed Rep
. 2019 Mar;
0(0):1-5.
PMID: 30842885
Circular RNAs (circRNAs) have been demonstrated to be biomarkers in human cancers. CircRNAs are majorly recognized in the transcript formation of eukaryotic genes. Research has also revealed that circRNAs regulate...
7.
Dogan Sigva Z, Balci Okcanoglu T, Biray Avci C, Yilmaz Susluer S, Kayabasi C, Turna B, et al.
Gene
. 2018 Nov;
687:261-271.
PMID: 30453074
Paclitaxel, which isolated from Taxus brevifolia, is recently started to be used against prostate cancer treatment and it is a very effective compound against cancer. In this study, we aimed...
8.
Yilmaz Susluer S, Kayabasi C, Ozmen Yelken B, Asik A, Celik D, Balci Okcanoglu T, et al.
Bosn J Basic Med Sci
. 2018 Apr;
18(2):150-161.
PMID: 29669510
Long non-coding RNAs (lncRNAs) have been implicated in numerous biological processes, including epigenetic regulation, cell-cycle control, and transcriptional/translational regulation of gene expression. Differential expression of lncRNAs and disruption of the...
9.
Asik A, Kayabasi C, Ozmen Yelken B, Yilmaz Susluer S, Dogan Sigva Z, Balci Okcanoglu T, et al.
Gene
. 2018 Jan;
647:213-220.
PMID: 29309887
Acute promyelocytic leukemia (APL) is a subtype of AML that is a mixture of hematological malignancy, characterized by a specific translocation t(15;17). The using of all-trans retinoic acid (ATRA) with...
10.
Kayabasi C, Balci Okcanoglu T, Ozmen Yelken B, Asik A, Yilmaz Susluer S, Biray Avci C, et al.
Gene
. 2017 Sep;
637:173-180.
PMID: 28942039
BCR-ABL tyrosine kinase inhibitors (TKIs) are selective therapies for the patients with Chronic Myeloid Leukemia (CML). Imatinib and ponatinib have remarkable long-term efficacy on a major molecular response. Although TKI...